Compare CCJ & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCJ | INSM |
|---|---|---|
| Founded | 1987 | 1988 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.6B | 41.2B |
| IPO Year | N/A | 2000 |
| Metric | CCJ | INSM |
|---|---|---|
| Price | $93.36 | $191.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 19 |
| Target Price | $114.38 | ★ $178.71 |
| AVG Volume (30 Days) | ★ 3.9M | 2.7M |
| Earning Date | 11-05-2025 | 10-30-2025 |
| Dividend Yield | ★ 0.18% | N/A |
| EPS Growth | ★ 364.36 | N/A |
| EPS | ★ 0.87 | N/A |
| Revenue | ★ $2,487,042,049.00 | $447,022,000.00 |
| Revenue This Year | $10.12 | $43.10 |
| Revenue Next Year | $6.89 | $128.25 |
| P/E Ratio | $108.09 | ★ N/A |
| Revenue Growth | 23.88 | ★ 30.34 |
| 52 Week Low | $35.00 | $60.40 |
| 52 Week High | $110.16 | $212.75 |
| Indicator | CCJ | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 57.31 | 44.31 |
| Support Level | $86.40 | $202.68 |
| Resistance Level | $93.88 | $206.69 |
| Average True Range (ATR) | 3.90 | 6.67 |
| MACD | 0.86 | -3.09 |
| Stochastic Oscillator | 92.83 | 0.91 |
Cameco Corp is a provider of uranium needed to generate clean, reliable baseload electricity around the globe. one of those uranium producers. It has three reportable segments, Uranium, Fuel Services, and Westinghouse. It derives maximum revenue from the Westinghouse Segment. It has some projects namely; Millennium, Yeelirrie, Kintyre, and Exploration. The company operates in Canada, Kazakhstan, Germany, Australia, and the United States.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.